Key facts
- Lucid Capital Markets initiated coverage of Microbot Medical stock.
- The rating assigned was a 'buy'.
Lucid Capital Markets has initiated coverage of Microbot Medical stock, assigning it a 'buy' rating. This move signals a positive perspective from Lucid Capital Markets regarding the potential performance of Microbot Medical's stock.